Jordan B. King

Jordan B. King, PharmD, MSCI

Languages spoken: English, Portuguese

Academic Information

Departments Primary - Population Health Sciences

Dr. King is currently an Assistant Professor of Population Health Sciences in the Division of Health System Innovation and Research and an Affiliate Investigator at the Institute for Health Research at Kaiser Permanente Colorado. His research is focused on improving medication use, particularly through the use of pharmacist-led health services. In particular, his lab has focused on anticoagulant management strategies, antihypertensive medication use and outcomes, and helping patients make unbiased decisions after experiencing statin-related side effects. His research has been published in the New England Journal of Medicine, The Journal of the American College of Cardiology, Diabetes Care, Hypertension, and JAMA Cardiology. He has been previously funded as a Principal Investigator by an AHRQ R18 (R18HS026156) and is currently funded by an NHLBI R01 (R01HL157439). He is also an NIH Loan Repayment Program awardee.

Dr. King received his Doctor of Pharmacy degree from Roseman University of Health Sciences, and his Masters of Science in Clinical Investigation from the University of Utah School of Medicine. He completed his post-doctoral research fellowship in Health Economics and Outcomes Research in the Pharmacotherapy Outcomes Research Center at the University of Utah College of Pharmacy.

Education History

Doctoral Training Roseman University of Health Sciences, College of Pharmacy
 PharmD
Graduate Training University of Utah, School of Medicine
 MSCI
Fellowship University of Utah, College of Pharmacy
 Fellow

Selected Publications

Journal Article

  1. Bress AP, Dodson JA, King JB, Sauer BC, Reese T, Crook J, Radwanski P, Knippenberg K, Greene T, Nelson RE, Munger MA, Weintraub WS, LaFleur (2018). Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris. The American journal of cardiology, 122(11), 1809-1816. (Read full article)
  2. Boniface KS, King JB, LeSaux MA, Haciski SC, Shokoohi (2020). Diagnostic Accuracy and Time-Saving Effects of Point-of-Care Ultrasonography in Patients With Small Bowel Obstruction: A Prospective Study. Annals of emergency medicine, 75(2), 246-256. (Read full article)
  3. King J, Bress A, Bellows (2017). Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Annals of internal medicine, 166(8), 606-607. (Read full article)
  4. Shokoohi H, Boniface KS, Loesche MA, Duggan NM, King J (2020). Development of a nomogram to predict small bowel obstruction using point-of-care ultrasound in the emergency department. The American journal of emergency medicine, 38(11), 2356-2360. (Read full article)
  5. Shokoohi H, Berry GW, Shahkolahi M, King JM, King JB, Salimian M, Poshtmashad A, Pourmand (2017). The diagnostic utility of sonographic carotid flow time in determining volume responsiveness. Journal of critical care, 38, 231-235. (Read full article)
  6. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension (Dallas, Tex., HYPERTENSIONAHA11912907. (Read full article)
  7. Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress A (2020). Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension (Dallas, Tex., 75(4), 973-981. (Read full article)
  8. Bress AP, King J (2019). Optimizing Medical Therapy in Chronic Worsening HFrEF: A Long Way to Go. Journal of the American College of Cardiology, 73(8), 945-947. (Read full article)
  9. Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, Gaussoin SA, Johnson KC, King J, Kitzman DW, Kostis JB, Lerner AJ, Lewis CE, Oparil S, Rahman M, Reboussin DM, Rocco MV, Snyder JK, Still C, Supiano MA, Wadley VG, Whelton PK, Wright JT Jr,, Williamson J (2019). Intensive vs Standard Blood Pressure Control in Adults 80¿Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. Journal of the American Geriatrics Society, 68(3), 496-504. (Read full article)
  10. Delate T, Charlu M, Zhu S, Pai A, Clark NP, Witt DM, King JM, King J (2020). Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thrombosis research, 196, 367-370. (Read full article)
  11. Caffiero NA, Nickman NA, Drews FA, King JB, Moorman K, Tyler L (2021). Reduction of phone interruptions post implementation of a central call center in community pharmacies of an academic health system. American journal of health-system pharmacy, 78(2), 113-121. (Read full article)
  12. Jones AE, King JB, Kim K, Witt D (2020). The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring. Journal of thrombosis and thrombolysis, 50(3), 739-745. (Read full article)
  13. Ruiz-Negrón N, Menon J, King JB, Ma J, Bellows B (2019). Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review. PharmacoEconomics, 37(5), 669-688. (Read full article)
  14. Derington CG, King JB, Bryant KB, McGee BT, Moran AE, Weintraub WS, Bellows BK, Bress A (2019). Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. Current hypertension reports, 21(12), 91. (Read full article)
  15. An J, Derington CG, Luong T, Olson KL, King JB, Bress AP, Jackevicius C (2020). Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. Current hypertension reports, 22(11), 95. (Read full article)
  16. Kuye R, Riggs C, King J, Heilmann R, Kurz D, Milchak (2020). Thyroid Stimulating Hormone Stability in Patients Prescribed Synthetic or Desiccated Thyroid Products: A Retrospective Study. Annals of family medicine,
  17. Derington CG, King JB, Delate T, Botts SR, Kroehl M, Kao DP, Trinkley K (2020). Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PloS one, 15(12), e0243371. (Read full article)
  18. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress A (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PloS one, 16(4), e0248080. (Read full article)
  19. Colvin CL, Poudel B, Bress AP, Derington CG, King JB, Wen Y, Chen L, Bittner V, Brown TM, Monda KL, Mues KE, Rosenson RS, Jackson EA, Muntner P, Colantonio L (2021). Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. Journal of clinical lipidology, 15(5), 665-673. (Read full article)
  20. Mohanty AF, Levitan EB, Dodson JA, Vardeny O, King JB, LaFleur J, He T, Patterson OV, Alba PR, Russo PA, Choi ME, Bress A (2019). Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Circulation. Heart failure, 12(11), e005691. (Read full article)
  21. Bellows BK, Ruiz-Negrón N, Bibbins-Domingo K, King JB, Pletcher MJ, Moran AE, Fontil (2019). Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals. Circulation. Cardiovascular quality and outcomes, 12(6), e005624. (Read full article)
  22. Owlia M, Dodson JA, King JB, Derington CG, Herrick JS, Sedlis SP, Crook J, DuVall SL, LaFleur J, Nelson R, Patterson OV, Shah RU, Bress A (2019). Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina. Journal of the American Heart Association, 8(15), e012811. (Read full article)
  23. Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, Fonseca V, Price-Haywood E, Guhl E, King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez AF, Cooper-DeHoff R (2019). PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. Journal of the American Heart Association, 8(9), e011246. (Read full article)
  24. Chelu MG, King JB, Kholmovski EG, Ma J, Gal P, Marashly Q, AlJuaid MA, Kaur G, Silver MA, Johnson KA, Suksaranjit P, Wilson BD, Han FT, Elvan A, Marrouche N (2018). Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging and Catheter Ablation of Atrial Fibrillation: 5-Year Follow-Up Data. Journal of the American Heart Association, 7(23), e006313. (Read full article)
  25. Bellows BK, Zhang Y, Zhang Z, Lloyd-Jones DM, Bress AP, King JB, Kolm P, Cushman WC, Johnson KC, Tamariz L, Oelsner EC, Shea S, Newman AB, Ives DG, Couper D, Moran AE, Weintraub W (2021). Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data. Journal of the American Heart Association, 10(10), e020361. (Read full article)
  26. Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, Poudel B, Monda KL, Navar AM, Mues KE, Stevens VW, Nelson RE, Vanneman ME, Muntner P, Bress A (2021). Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association, 10(8), e019254. (Read full article)
  27. Bryant KB, Sheppard JP, Ruiz-Negrón N, Kronish IM, Fontil V, King JB, Pletcher MJ, Bibbins-Domingo K, Moran AE, McManus RJ, Bellows B (2020). Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control. Journal of the American Heart Association, 9(15), e016174. (Read full article)
  28. Hawkins KL, King J, Delate T, Martinez K, McCool K, Clark N (2018). Pharmacy Technician Management of Stable, In-Range INRs Within a Clinical Pharmacy Anticoagulation Service. Journal of managed care & specialty pharmacy, 24(11), 1130-1137. (Read full article)
  29. Li S, Schwartz JE, Shimbo D, Muntner P, Shikany JM, Booth JN 3rd, Allen NB, Jaeger BC, Bress AP, King JB, Clark D 3rd, Butler KR, Correa A, Moran AE, Bellows BK, Zhang (2021). Estimated Prevalence of Masked Asleep Hypertension in US Adults. JAMA cardiology, 6(5), 568-573. (Read full article)
  30. Colvin CL, King JB, Oparil S, Wright JT Jr, Ogedegbe G, Mohanty A, Hardy ST, Huang L, Hess R, Muntner P, Bress (2020). Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. JAMA network open, 3(11), e2025127. (Read full article)
  31. Mohanty AF, Levitan EB, King JB, Dodson JA, Vardeny O, Cook J, Herrick JS, He T, Patterson OV, Alba PR, Russo PA, Obi EN, Choi ME, Fang JC, Bress A (2021). Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association, 10(20), e020474. (Read full article)
  32. Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial (SPRINT) Research Group (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA network open, 5(1), e2145319. (Read full article)
  33. Green MB, Shimbo D, Schwartz JE, Bress AP, King JB, Muntner P, Sheppard JP, McManus RJ, Kohli-Lynch CN, Zhang Y, Shea S, Moran AE, Bellows B (2022). Cost-Effectiveness of Masked Hypertension Screening and Treatment in US Adults With Suspected Masked Hypertension: A Simulation Study. American journal of hypertension, 35(8), 752-762. (Read full article)
  34. Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial (SPRINT) Research Grou (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA network open, 5(7), e2220680. (Read full article)
  35. Bellows BK, Xu J, Sheppard JP, Schwartz JE, Shimbo D, Muntner P, McManus RJ, Moran AE, Bryant KB, Cohen LP, Bress AP, King JB, Shikany JM, Green BB, Yano Y, Clark D, Zhang (2022). Predicting Out-of-Office Blood Pressure in a Diverse US Population. American journal of hypertension, 35(6), 533-542. (Read full article)
  36. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, Dixon DL, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress A (2022). Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. American heart journal, 248, 150-159. (Read full article)
  37. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA network open, 5(2), e2148172. (Read full article)
  38. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress A (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 5(1), e2143001. (Read full article)
  39. King JB, Pinheiro LC, Bryan Ringel J, Bress AP, Shimbo D, Muntner P, Reynolds K, Cushman M, Howard G, Manly JJ, Safford M (2022). Multiple Social Vulnerabilities to Health Disparities and Hypertension and Death in the REGARDS Study. Hypertension (Dallas, Tex., 79(1), 196-206. (Read full article)
  40. Mangrum JS, Saunders JA, Chaiyakunapruk N, Witt DM, King J (2023). A scoping review of direct oral anticoagulant ambulatory management practices. Journal of thrombosis and thrombolysis, (Read full article)
  41. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA cardiology, 8(5), 443-452. (Read full article)
  42. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King J (2023). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 80(3), 590-597. (Read full article)
  43. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King J (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. Journal of the American Heart Association, 12(11), e028573. (Read full article)
  44. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress A (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA network open, 6(5), e2314443. (Read full article)
  45. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen J (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. Journal of the American Heart Association, 12(17), e030311. (Read full article)
  46. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress A (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension (Dallas, Tex., 80(8), 1749-1758. (Read full article)
  47. Derington CG, Goodrich GK, Xu S, Clark NP, Reynolds K, An J, Witt DM, Smith DH, O'Keeffe-Rosetti M, Lang DT, Ho PM, Cheetham TC, Comer AC, King J (2023). Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation. JAMA network open, 6(7), e2321971. (Read full article)
  48. Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress A (2023). Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. American journal of preventive cardiology, 17, 100624. (Read full article)
  49. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress A (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Journal of the American Heart Association, 13(3), e031574. (Read full article)
  50. Zhang F, Bryant KB, Moran AE, Zhang Y, Cohen JB, Bress AP, Sheppard JP, King JB, Derington CG, Weintraub WS, Kronish IM, Shea S, Bellows B (2024). Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study. Journal of the American Heart Association, 13(2), e032370. (Read full article)
  51. Jacobs JA, Rodgers A, Bellows BK, Hernandez I, Wang N, Derington CG, King JB, Zheutlin AR, Whelton PK, Egan BM, Cushman WC, Bress A (2024). Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. Hypertension (Dallas, Tex., 81(11), 2307-2317. (Read full article)
  52. King JB, Sakhuja S, Derington CG, Kolm P, Herrick JS, Berchie RO, Shen J, Greene T, Tajeu GS, Howard G, Levitan EB, Muntner P, Safford MM, Ying J, Weintraub WS, Moran AE, Bress AP, Bellows B (2024). Annual Cost of Implementing Intensive Systolic Blood Pressure Goals in the United States. Journal of the American Heart Association, 13(18), e034515. (Read full article)
  53. Derington CG, Berchie RO, Scharfstein DO, Andrews RM, Greene TH, Xu Y, King JB, Supiano MA, Sonnen JA, Williamson J, Pajewski NM, Pruzin J, Cohen JB, Bress A (2025). Effect of initiation and continuous adherence to ARBs vs. ACEIs on risk of adjudicated mild cognitive impairment or dementia. The journals of gerontology. Series A, Biological sciences and medical sciences, 80(7), (Read full article)
  54. Hong H, Wilson AS, Jones AE, Vazquez SR, Gilbert S, Malone DC, Chaiyakunapruk N, King JB, Barnes GD, Sylvester KW, Dube G, Irving NV, Chan L, Ragheb B, Delate T, Witt D (2025). Overcoming Barriers to Warfarin Patient Self-Management (PSM) in the US Healthcare System: Implementation Trial Study Protocol. (Read full article)
  55. Derington CG, Berchie RO, Mohanty AF, Jacobs JA, Xu Y, King JB, Rethy L, Cushman WC, Zickmund SL, Ho PM, Raghavan S, Cohen JB, Bress A (2025). First-Line ß-Blocker Use for Hypertension in the Veterans Health Administration. JAMA network open, 8(8), e2529026. (Read full article)
  56. Wong KH, Zeng E, Smith TL, King JB, Marini E, Sorenson A, Hwang H, Stein C, Francis T, Rose JW, Reddy VK, de Havenon AH, Clardy S (2025). Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies. JAMA network open, 8(10), e2538277. (Read full article)